ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Brener Z., 1979. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the western hemisphere. Pharmacol. Therapeut., 7 :71–90.
-
2.
Gutteridge W. E., 1981. Chemotherapy of Chagas' disease. Pages 47–57 inBaker J. R., eds., Perspectives in Trypanosomiasis Research., Proc. 21st Trypanosomiasis Seminar, London. Research Studies Press, Chichester.
-
3.
Duncan B. 1982. American trypanosomiasis (Chagas' disease). Pages 1437–1445 inWedgwood R. J., Davis S.D., Ray C. G., Kelley V. C., eds., Infections in Children, Harper and Row, Philadelphia.
-
4.
McCabe R. E., Araujo F. S., Remington J. S., 1983. Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. Am. J. Trap. Med. Hyg., 32 :960–962.
-
5.
McCabe R. E., Remington J. S., Araujo F. S., 1984. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J. Infect. Dis., 150 :594–601.
-
6.
Sanderson C.J., Thomas J. A., Twomey C. E., 1980. The growth of Trypanosoma cruzi in human diploid cells for the production of trypomastigotes. Parasitology, 80 :153–162.
-
7.
Ribeiro L. V., Kimura E., Fernandes J. F., 1969. Factors affecting the density of intracellular infection of tissue culture cells by Trypanosoma cruzi. Rev. Brasil. Bioi., 29 :295–308.
-
8.
Finney D. J., 1964. Probit Analysis, Second edition. Cambridge University Press, London.
-
9.
Wilson H. R., Ptacek B., 1974. Use of the C3H mouse in experimental chemotherapy of Chagas' disease. Third Inti. Congr. Parasitol. Proc., 3 :1293–1294.
-
10.
Wilson H. R., Revankar G. R., Tolman R. L., 1974. In vitro and in vivo activity of certain thiosemicarbazones against Trypanosoma cruzi. J. Med. Chem., 17 :760–761.
-
11.
Maxwell A. E. 1961. Analyzing Quantitative Data. Spottiswoode, Ballantyne and Co., Ltd., London. 13–23.
-
12.
Brener Z., Chiari E., 1971. The effects of some immunosuppressive agents in experimental Chagas' disease. Trans. R. Soc. Trap. Med. Hyg., 65 :629–636.
-
13.
Martinez-Silva R., Lopez V. A., Colon J. I., Chiriboga J., 1969. Isolation of Trypanosoma cruzi from blood of acutely and chronically infected mice in tissue culture. Am. J. Trop. Med. Hyg., 18 :878–884.
-
14.
Murray P. K., Habbersett M. C., Meurer R. D., 1983. Trypanosoma cruzi: Efficacy of the 2-substituted, 5-nitroimidazoles, MK-436 and L634, 549, in tissue culture and mice. Am. J. Trop. Med. Hyg., 32 :1242–1250.
-
15.
Raether W., Seidenath H., 1984. Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei, and Entamoeba histolylica in vivo. Z. Parasitemia, 70 :135–138.
.png)
The Efficacy of an N-Substituted Imidazole, RS-49676, Against a Trypanosoma Cruzi Infection in Mice
In vitro studies against epimastigotes and intracellular amastigotes and in vivo studies in inbred C3H/He mice infected with Trypanosoma cruzi Brazil strain were performed to determine the activities of two N-substituted imidazole compounds, RS- 49676 and ketoconazole. Both compounds are extremely active in vitro against the amastigotes (ED50 <0.0001 μg/ml) yet inactive against the epimastigotes. In vivo, RS-49676 increased the mean survival time over 11 weeks beyond the untreated control when given subcutaneously twice daily at 100 mg/kg/day. Ketoconazole increased the mean survival time 11-18 days beyond the untreated control (mean survival time 22 days) when given subcutaneously twice daily at 100 mg/kg or orally once daily at 100 mg/kg. Approximately 20%-25% of the RS-49676 treated mice were cured as determined by culturing the blood of infected mice with fibroblast lung cells. None of the ketoconazole mice were cured.